Company intelligence / Profile preview

Lineage Cell Therapeutics

Carlsbad, California, USAlineagecell.com ↗
Ownership
Public · LCTX
Development stage
Other
01

Overview

OpRegen® has shown promising results in a Phase 2a trial under collaboration with Roche/Genentech targeting geographic atrophy in AMD patients. The program has received RMAT designation by FDA. OPC1 is in early phase clinical trials showing initial safety and efficacy signals for spinal cord injury treatment. VAC2 is undergoing Phase I trials as an immuno-oncology candidate[5][6][10].

Therapeutic areas
OphthalmologyOncologyNeurology
Modalities
Allogeneic ("off-the-shelf") cell therapies derived from pluripotent stem cellsRetinal pigment epithelial cellsOligodendrocyte progenitor cellsAuditory neuronal progenitor cellsPhotoreceptor neural cellsDendritic cell immunotherapies
Industry
Biotech
02

Drug pipeline

13 assets

hextend

Approved

12 more assets in the full pipeline.

03

Partnerships

Roche / Genentech collaboration on OpRegen® retinal therapy program[4][5]License agreement with Eterna Therapeutics Inc for gene-edited hypoimmune iPSC lines[4]
04

Financials

Market cap
$248.6M
Total revenue
$14.6M
Enterprise value
$200.1M

Beyond the preview

Go deeper on Lineage Cell Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lineage Cell Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call